KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Operating Leases (2019 - 2025)

Amneal Pharmaceuticals (AMRX) has 7 years of Operating Leases data on record, last reported at $58.8 million in Q4 2025.

  • For Q4 2025, Operating Leases rose 526.14% year-over-year to $58.8 million; the TTM value through Dec 2025 reached $58.8 million, up 526.14%, while the annual FY2025 figure was $58.8 million, 526.14% up from the prior year.
  • Operating Leases reached $58.8 million in Q4 2025 per AMRX's latest filing, up from $15.7 million in the prior quarter.
  • Across five years, Operating Leases topped out at $64.0 million in Q4 2021 and bottomed at $9.4 million in Q4 2024.
  • Average Operating Leases over 5 years is $29.2 million, with a median of $26.6 million recorded in 2022.
  • Peak YoY movement for Operating Leases: tumbled 80.8% in 2024, then surged 526.14% in 2025.
  • A 5-year view of Operating Leases shows it stood at $64.0 million in 2021, then decreased by 7.45% to $59.2 million in 2022, then dropped by 17.42% to $48.9 million in 2023, then tumbled by 80.8% to $9.4 million in 2024, then soared by 526.14% to $58.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $58.8 million in Q4 2025, $15.7 million in Q3 2025, and $16.4 million in Q2 2025.